Microcap Ledger CervoMed Inc. $CRVO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Boston, MA
- Fiscal year end
- December 31
- Shares outstanding
- 15,119,096 [10-Q 2026-08-07]
What the company doesAI summary of filing
CervoMed Inc. is a clinical-stage biotechnology company developing neflamapimod, an investigational small-molecule drug that selectively inhibits p38α to address neuroinflammation and synaptic dysfunction in age-related brain disorders. The company is not currently revenue-generating. Neflamapimod is in clinical development for dementia with Lewy bodies (the lead indication), non-fluent variant primary progressive aphasia, recovery after ischemic stroke, and amyotrophic lateral sclerosis, with the company planning to initiate a Phase 3 trial in DLB in the second half of 2026 subject to funding. [10-K 2026-03-13]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $0.00 | −$14.54M | −$14.94M | $22.46M | [10-Q 2026-08-07] |
| FY ended Dec 2025 | $4.01M | −$26.97M | −$23.45M | $8.24M | [10-K 2026-03-13] |
| FY ended Dec 2024 | $9.74M | −$16.29M | −$16.53M | $9.00M | [10-K 2026-03-13] |
- Quarterly cash burn
- −$7.47M
- Cash runway Estimate
- ~9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-07 | 8,253,741 | [10-Q 2024-11-12] |
| 2025-03-14 | 8,702,719 | [10-K 2025-03-17] |
| 2025-05-09 | 8,702,719 | [10-Q 2025-05-12] |
| 2025-08-06 | 9,252,719 | [10-Q 2025-08-08] |
| 2025-11-05 | 9,252,719 | [10-Q 2025-11-07] |
| 2026-03-12 | 9,258,719 | [10-K 2026-03-13] |
| 2026-05-06 | 9,258,719 | [10-Q 2026-05-15] |
| 2026-08-06 | 15,119,096 | [10-Q 2026-08-07] |
- Shelf registration
- S-3 filed 2026-07-06; declared effective 2026-07-10 [S-3 2026-07-06]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-11 | Boger Joshua S | buy | 955,414 | $3.14 | [4 2026-06-15] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | 8-K | Regulation FD disclosure |
| 2026-09-28 | 8-K | Regulation FD disclosure; Other events |
| 2026-09-10 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-10 | 8-K | Results of operations |
| 2026-08-07 | 10-Q | Quarterly report |
| 2026-08-04 | 8-K | Regulation FD disclosure; Other events |
| 2026-07-14 | 8-K | Regulation FD disclosure; Other events |
| 2026-07-10 | 424B3 | Prospectus or prospectus supplement |
Alerts for $CRVO
Email me when CervoMed Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.